PMID- 34255094
OWN - NLM
STAT- MEDLINE
DCOM- 20220330
LR  - 20220401
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Print)
IS  - 0179-7158 (Linking)
VI  - 198
IP  - 2
DP  - 2022 Feb
TI  - 12 x 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in 
      response between lung metastases and primary bronchial carcinoma?
PG  - 110-122
LID - 10.1007/s00066-021-01811-3 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the safety and long-term tumor 
      control after stereotactic radiotherapy (SRT) with 12 x 6 Gy of patients with 
      primary bronchial carcinoma (BC) or with pulmonary metastases (MET) of various 
      solid tumors. Local progression-free survival (LPFS), progression-free survival 
      (PFS), overall survival (OS), and prognostic factors were compared. METHODS: 
      Between May 2012 and January 2020, 168 patients with 206 pulmonary lesions (170 
      MET and 36 primary BC) were treated with 12 x 6 Gy (BED(10) 116 Gy). The 
      irradiated pulmonary MET were from the following cancers: 47 (27.6%) head and 
      neck, 37 (21.8%) rectum or colon, 30 (17.6%) bronchial, 13 (7.6%) malignant 
      melanoma, 9 (5.3%) esophageal, 9 (5.3%) sarcoma, and 25 (14.8%) other. RESULTS: 
      The median follow-up was 16.26 months (range: 0.46-89.34) for BC and 19.18 months 
      (0.89-91.11) for MET. Survival rates at 3 years were: OS 43% for BC and 35% for 
      MET; LPFS BC 96% and MET 85%; PFS BC 35% and MET 29%. The most frequently 
      observed grade 3 adverse events (AEs) were pneumonitis (5.9% BC, 4.8% MET), 
      pulmonary fibrosis (2.9% BC, 4% MET), and pulmonary embolism (2.9% BC, 0.8% MET). 
      The favorable prognostic effects on overall survival of patients with MET were 
      female gender (log-rank: p < 0.001), no systemic progression (log-rank; 
      p = 0.048, multivariate COX regression p = 0.039), and malignant melanoma 
      histology (log-rank; p = 0.015, multivariate COX regression p = 0.020). For 
      patients with BC, it was tumor location within the lower lobe (vs. upper lobe, 
      log-rank p = 0.027). LPFS of patients with metastatic disease was beneficially 
      influenced by female gender (log-rank: p = 0.049). CONCLUSION: The treatment 
      concept of 12 x 6 Gy is associated with 96% local progression-free survival for 
      BC and 85% for pulmonary metastases after 3 years. There was no difference in 
      response after SRT of primary lung carcinoma or pulmonary metastases.
CI  - (c) 2021. The Author(s).
FAU - Lubgan, Dorota
AU  - Lubgan D
AUID- ORCID: 0000-0002-2569-3814
AD  - Department of Radiation Oncology, Erlangen University Hospital, 
      Universitatsstrasse 29, 91054, Erlangen, Germany. dorota.lubgan@uk-erlangen.de.
FAU - Semrau, Sabine
AU  - Semrau S
AD  - Department of Radiation Oncology, Erlangen University Hospital, 
      Universitatsstrasse 29, 91054, Erlangen, Germany.
FAU - Lambrecht, Ulrike
AU  - Lambrecht U
AD  - Department of Radiation Oncology, Erlangen University Hospital, 
      Universitatsstrasse 29, 91054, Erlangen, Germany.
FAU - Gaipl, Udo S
AU  - Gaipl US
AD  - Department of Radiation Oncology, Erlangen University Hospital, 
      Universitatsstrasse 29, 91054, Erlangen, Germany.
FAU - Fietkau, Rainer
AU  - Fietkau R
AD  - Department of Radiation Oncology, Erlangen University Hospital, 
      Universitatsstrasse 29, 91054, Erlangen, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210713
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - *Carcinoma, Bronchogenic/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Lung Neoplasms/pathology
MH  - Prognosis
MH  - *Radiosurgery/adverse effects
MH  - Retrospective Studies
PMC - PMC8789716
OTO - NOTNLM
OT  - Primary lung cancer
OT  - Prognostic factor
OT  - Progression-free survival
OT  - Pulmonary lesion
OT  - Stereotactic irradiation
COIS- D. Lubgan, S. Semrau, U. Lambrecht, U.S. Gaipl, and R. Fietkau declare that they 
      have no competing interests.
EDAT- 2021/07/14 06:00
MHDA- 2022/03/31 06:00
PMCR- 2021/07/13
CRDT- 2021/07/13 12:23
PHST- 2021/03/08 00:00 [received]
PHST- 2021/06/18 00:00 [accepted]
PHST- 2021/07/14 06:00 [pubmed]
PHST- 2022/03/31 06:00 [medline]
PHST- 2021/07/13 12:23 [entrez]
PHST- 2021/07/13 00:00 [pmc-release]
AID - 10.1007/s00066-021-01811-3 [pii]
AID - 1811 [pii]
AID - 10.1007/s00066-021-01811-3 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2022 Feb;198(2):110-122. doi: 10.1007/s00066-021-01811-3. 
      Epub 2021 Jul 13.